Company Filing History:

14 out of 589

Kowa Company Limited

patents

1 out of 168

The University of Edinburgh

patents

1 out of 149

University of Strathclyde

patents

where one patent can have more than one assignee

Years Active: 2001-2012

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8268789 - PAR-2 antagonists (2012-09-18),

2. 8133864 - PAR-2 agonist (2012-03-13),

3. 7910556 - PAR-2 agonist (2011-03-22),

4. 7541339 - Par-2-activating peptide derivative and pharmaceutical composition using the same (2009-06-02),

5. 7196101 - Bis(5-aryl-2-pyridyl) derivatives (2007-03-27),

6. 6890940 - Bis(2-aryl-5-pyridyl) derivatives (2005-05-10),

7. 6828316 - Diamide compound and medicine containing the same (2004-12-07),

8. 6787653 - Preparation process of biphenylcarboxylic acid amide derivatives (2004-09-07),

9. 6706703 - Bis(5-aryl-2-pyridyl) derivatives (2004-03-16),

10. 6645957 - Cyclic amide compound (2003-11-11),

11. 6576642 - Diamide compounds and compositions containing the same (2003-06-10),

12. 6448242 - Cyclic amide compounds (2002-09-10),

13. 6340682 - Diamide compound and drugs containing the same (2002-01-22),

14. 6297283 - Diamide compounds and compositions containing the same (2001-10-02),

Title: **Mototsugu Kabeya: Innovator in PAR-2 Therapeutics**

Introduction

Mototsugu Kabeya is a notable inventor hailing from Higashimurayama, Japan. With an impressive portfolio of 14 patents, his work focuses primarily on advancing therapies related to the protease-activated receptor 2 (PAR-2). His inventions are significant contributions to the pharmaceutical field, particularly in creating compounds that exhibit potential therapeutic benefits against various diseases.

Latest Patents

Among his latest patents, Kabeya has developed PAR-2 antagonists, characterized by the general formula (1), which includes innovative compounds and their salicylic or solvated forms. These antagonists serve as preventive or therapeutic agents for PAR-2 related diseases. Additionally, he has produced a pharmaceutical composition aimed at preventing or treating conditions associated with PAR-2. The patented drug compositions have demonstrated improved PAR-2 activation potency when compared to existing peptide therapies, highlighting his contributions to enhancing pharmaceutical efficacy.

Career Highlights

Throughout his career, Kabeya has made substantial strides in drug development, making significant contributions while working with Kowa Company Limited and the University of Edinburgh. His dedication to research and development is evident through his numerous patents, showcasing his innovative spirit and commitment to medical advancements.

Collaborations

Kabeya has collaborated with notable professionals, including Hiroyuki Ishiwata and Seiichi Sato. These partnerships have likely propelled his research forward, enriching the field of pharmacology with their combined expertise and insights into therapeutic development.

Conclusion

Mototsugu Kabeya is a distinguished inventor whose work has greatly impacted the landscape of pharmaceutical innovations related to PAR-2. His patents mark a significant evolution in the development of therapeutic agents, making him a key figure in modern medical research. As the medical field continues to advance, Kabeya's contributions promise to play a vital role in future therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.